pdf   xlsx method abbreviations

breast cancer (BC), ... versus trastuzumab based treatment, meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.62 [0.30, 1.27]< 10%1 study (1/-)90.5 %NAnot evaluable crucial-
deaths (OS) (extension) 0.72 [0.41, 1.27]< 10%1 study (1/-)87.3 %NAnot evaluable important-
events or deaths (EFS) 0.78 [0.47, 1.29]< 10%1 study (1/-)83.4 %NAnot evaluable non important-
events or deaths (EFS) (extended) 0.81 [0.52, 1.26]< 10%1 study (1/-)82.5 %NAnot evaluable non important-
pCR 2.60 [1.49, 4.54]> 10%1 study (1/-)100.0 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.